Volume 85, Number 1 (2002), in the article “Is Lack of Response to Single-Agent Chemotherapy in Gestational Trophoblastic Disease Associated with Dose Scheduling or Chemotherapy Resistance?,” by Ernest I. Kohorn, pages 36–39 (doi:10.1006/gyno.2001.6533)

By  

Gynecologic Oncology, Vol. 86, Iss. 1, 2002-07 ,pp. : 104-104

Academic Press

Access to resources Recommend Favorite

Experience with platinum-based and high-dose chemotherapy in patients with gestational trophoblastic disease: possible implications for future management

By Markman Maurie  

Journal of Cancer Research and Clinical Oncology, Vol. 130, Iss. 7, 2004-07 ,pp. : 383-387

Springer Publishing Company

Access to resources Recommend Favorite

Gestational Trophoblastic Disease: A Study of Mode of Evacuation and Subsequent Need for Treatment with Chemotherapy

By Tidy J.A.   Gillespie A.M.   Bright N.   Radstone C.R.   Coleman R.E.   Hancock B.W.  

Gynecologic Oncology, Vol. 78, Iss. 3, 2000-09 ,pp. : 309-312

Elsevier

Access to resources Recommend Favorite

Chemotherapy for gestational trophoblastic tumours hastens menopause by 3 years

By Bower M.   Rustin G.J.S.   Newlands E.S.   Holden L.   Short D.   Foskett M.   Bagshawe K.D.  

European Journal of Cancer, Vol. 34, Iss. 8, 1998-07 ,pp. : 1204-1207

Elsevier

Access to resources Recommend Favorite

A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG

By Banerjee S.   Rustin G.   Paul J.   Williams C.   Pledge S.   Gabra H.   Skailes G.   Lamont A.   Hindley A.   Goss G.   Gilby E.   Hogg M.   Harper P.   Kipps E.   Lewsley L-A   Hall M.   Vasey P.   Kaye S. B.  

Annals of Oncology, Vol. 24, Iss. 3, 2013-03 ,pp. : 679-687

Oxford University Press

Access to resources Recommend Favorite